Complementary therapy for prevention and treatment of hemophilia A acquired coagulation factor 鈪� deficiency and von Willebrand's disease
The global Human Factor VIII Concentrate market was valued at US$ 185 million in 2023 and is anticipated to reach US$ 242.9 million by 2030, witnessing a CAGR of 4.0% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Human Factor VIII Concentrate, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Factor VIII Concentrate.
Report Scope
The Human Factor VIII Concentrate market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Human Factor VIII Concentrate market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Human Factor VIII Concentrate manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Pfizer
Novo Nordisk A/S
Shire (Baxter)
Bayer
GC Pharma
Shanghai Raas Corp
Hualan Biological
Shandong Taibang Biological Products
Shanghai Xinxing Medicine
SinoCell Tech
CSL
Grifols
Biogen
Octapharma
NovoNordisk
Segment by Type
Blood Extraction
Recombine
Segment by Application
Congenital Coagulation Factor VIII Deficiency
Acquired Factor VIII Deficiency
Von Willebrand's Disease
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Human Factor VIII Concentrate manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Human Factor VIII Concentrate in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Human Factor VIII Concentrate 麻豆原创 Overview
1.1 Product Overview and Scope of Human Factor VIII Concentrate
1.2 Human Factor VIII Concentrate Segment by Type
1.2.1 Global Human Factor VIII Concentrate 麻豆原创 Value Comparison by Type (2024-2030)
1.2.2 Blood Extraction
1.2.3 Recombine
1.3 Human Factor VIII Concentrate Segment by Application
1.3.1 Global Human Factor VIII Concentrate 麻豆原创 Value by Application: (2024-2030)
1.3.2 Congenital Coagulation Factor VIII Deficiency
1.3.3 Acquired Factor VIII Deficiency
1.3.4 Von Willebrand's Disease
1.4 Global Human Factor VIII Concentrate 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Human Factor VIII Concentrate Revenue 2019-2030
1.4.2 Global Human Factor VIII Concentrate Sales 2019-2030
1.4.3 Global Human Factor VIII Concentrate 麻豆原创 Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Human Factor VIII Concentrate 麻豆原创 Competition by Manufacturers
2.1 Global Human Factor VIII Concentrate Sales 麻豆原创 Share by Manufacturers (2019-2024)
2.2 Global Human Factor VIII Concentrate Revenue 麻豆原创 Share by Manufacturers (2019-2024)
2.3 Global Human Factor VIII Concentrate Average Price by Manufacturers (2019-2024)
2.4 Global Human Factor VIII Concentrate Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Human Factor VIII Concentrate, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Human Factor VIII Concentrate, Product Type & Application
2.7 Human Factor VIII Concentrate 麻豆原创 Competitive Situation and Trends
2.7.1 Human Factor VIII Concentrate 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Human Factor VIII Concentrate Players 麻豆原创 Share by Revenue
2.7.3 Global Human Factor VIII Concentrate 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Human Factor VIII Concentrate Retrospective 麻豆原创 Scenario by Region
3.1 Global Human Factor VIII Concentrate 麻豆原创 Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Human Factor VIII Concentrate Global Human Factor VIII Concentrate Sales by Region: 2019-2030
3.2.1 Global Human Factor VIII Concentrate Sales by Region: 2019-2024
3.2.2 Global Human Factor VIII Concentrate Sales by Region: 2025-2030
3.3 Global Human Factor VIII Concentrate Global Human Factor VIII Concentrate Revenue by Region: 2019-2030
3.3.1 Global Human Factor VIII Concentrate Revenue by Region: 2019-2024
3.3.2 Global Human Factor VIII Concentrate Revenue by Region: 2025-2030
3.4 North America Human Factor VIII Concentrate 麻豆原创 Facts & Figures by Country
3.4.1 North America Human Factor VIII Concentrate 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Human Factor VIII Concentrate Sales by Country (2019-2030)
3.4.3 North America Human Factor VIII Concentrate Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Human Factor VIII Concentrate 麻豆原创 Facts & Figures by Country
3.5.1 Europe Human Factor VIII Concentrate 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Human Factor VIII Concentrate Sales by Country (2019-2030)
3.5.3 Europe Human Factor VIII Concentrate Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Human Factor VIII Concentrate 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific Human Factor VIII Concentrate 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Human Factor VIII Concentrate Sales by Country (2019-2030)
3.6.3 Asia Pacific Human Factor VIII Concentrate Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Human Factor VIII Concentrate 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Human Factor VIII Concentrate 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Human Factor VIII Concentrate Sales by Country (2019-2030)
3.7.3 Latin America Human Factor VIII Concentrate Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Human Factor VIII Concentrate 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Human Factor VIII Concentrate 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Human Factor VIII Concentrate Sales by Country (2019-2030)
3.8.3 Middle East and Africa Human Factor VIII Concentrate Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Human Factor VIII Concentrate Sales by Type (2019-2030)
4.1.1 Global Human Factor VIII Concentrate Sales by Type (2019-2024)
4.1.2 Global Human Factor VIII Concentrate Sales by Type (2025-2030)
4.1.3 Global Human Factor VIII Concentrate Sales 麻豆原创 Share by Type (2019-2030)
4.2 Global Human Factor VIII Concentrate Revenue by Type (2019-2030)
4.2.1 Global Human Factor VIII Concentrate Revenue by Type (2019-2024)
4.2.2 Global Human Factor VIII Concentrate Revenue by Type (2025-2030)
4.2.3 Global Human Factor VIII Concentrate Revenue 麻豆原创 Share by Type (2019-2030)
4.3 Global Human Factor VIII Concentrate Price by Type (2019-2030)
5 Segment by Application
5.1 Global Human Factor VIII Concentrate Sales by Application (2019-2030)
5.1.1 Global Human Factor VIII Concentrate Sales by Application (2019-2024)
5.1.2 Global Human Factor VIII Concentrate Sales by Application (2025-2030)
5.1.3 Global Human Factor VIII Concentrate Sales 麻豆原创 Share by Application (2019-2030)
5.2 Global Human Factor VIII Concentrate Revenue by Application (2019-2030)
5.2.1 Global Human Factor VIII Concentrate Revenue by Application (2019-2024)
5.2.2 Global Human Factor VIII Concentrate Revenue by Application (2025-2030)
5.2.3 Global Human Factor VIII Concentrate Revenue 麻豆原创 Share by Application (2019-2030)
5.3 Global Human Factor VIII Concentrate Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Human Factor VIII Concentrate Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Pfizer Human Factor VIII Concentrate Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Novo Nordisk A/S
6.2.1 Novo Nordisk A/S Corporation Information
6.2.2 Novo Nordisk A/S Description and Business Overview
6.2.3 Novo Nordisk A/S Human Factor VIII Concentrate Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Novo Nordisk A/S Human Factor VIII Concentrate Product Portfolio
6.2.5 Novo Nordisk A/S Recent Developments/Updates
6.3 Shire (Baxter)
6.3.1 Shire (Baxter) Corporation Information
6.3.2 Shire (Baxter) Description and Business Overview
6.3.3 Shire (Baxter) Human Factor VIII Concentrate Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Shire (Baxter) Human Factor VIII Concentrate Product Portfolio
6.3.5 Shire (Baxter) Recent Developments/Updates
6.4 Bayer
6.4.1 Bayer Corporation Information
6.4.2 Bayer Description and Business Overview
6.4.3 Bayer Human Factor VIII Concentrate Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Bayer Human Factor VIII Concentrate Product Portfolio
6.4.5 Bayer Recent Developments/Updates
6.5 GC Pharma
6.5.1 GC Pharma Corporation Information
6.5.2 GC Pharma Description and Business Overview
6.5.3 GC Pharma Human Factor VIII Concentrate Sales, Revenue and Gross Margin (2019-2024)
6.5.4 GC Pharma Human Factor VIII Concentrate Product Portfolio
6.5.5 GC Pharma Recent Developments/Updates
6.6 Shanghai Raas Corp
6.6.1 Shanghai Raas Corp Corporation Information
6.6.2 Shanghai Raas Corp Description and Business Overview
6.6.3 Shanghai Raas Corp Human Factor VIII Concentrate Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Shanghai Raas Corp Human Factor VIII Concentrate Product Portfolio
6.6.5 Shanghai Raas Corp Recent Developments/Updates
6.7 Hualan Biological
6.6.1 Hualan Biological Corporation Information
6.6.2 Hualan Biological Description and Business Overview
6.6.3 Hualan Biological Human Factor VIII Concentrate Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Hualan Biological Human Factor VIII Concentrate Product Portfolio
6.7.5 Hualan Biological Recent Developments/Updates
6.8 Shandong Taibang Biological Products
6.8.1 Shandong Taibang Biological Products Corporation Information
6.8.2 Shandong Taibang Biological Products Description and Business Overview
6.8.3 Shandong Taibang Biological Products Human Factor VIII Concentrate Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Shandong Taibang Biological Products Human Factor VIII Concentrate Product Portfolio
6.8.5 Shandong Taibang Biological Products Recent Developments/Updates
6.9 Shanghai Xinxing Medicine
6.9.1 Shanghai Xinxing Medicine Corporation Information
6.9.2 Shanghai Xinxing Medicine Description and Business Overview
6.9.3 Shanghai Xinxing Medicine Human Factor VIII Concentrate Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Shanghai Xinxing Medicine Human Factor VIII Concentrate Product Portfolio
6.9.5 Shanghai Xinxing Medicine Recent Developments/Updates
6.10 SinoCell Tech
6.10.1 SinoCell Tech Corporation Information
6.10.2 SinoCell Tech Description and Business Overview
6.10.3 SinoCell Tech Human Factor VIII Concentrate Sales, Revenue and Gross Margin (2019-2024)
6.10.4 SinoCell Tech Human Factor VIII Concentrate Product Portfolio
6.10.5 SinoCell Tech Recent Developments/Updates
6.11 CSL
6.11.1 CSL Corporation Information
6.11.2 CSL Human Factor VIII Concentrate Description and Business Overview
6.11.3 CSL Human Factor VIII Concentrate Sales, Revenue and Gross Margin (2019-2024)
6.11.4 CSL Human Factor VIII Concentrate Product Portfolio
6.11.5 CSL Recent Developments/Updates
6.12 Grifols
6.12.1 Grifols Corporation Information
6.12.2 Grifols Human Factor VIII Concentrate Description and Business Overview
6.12.3 Grifols Human Factor VIII Concentrate Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Grifols Human Factor VIII Concentrate Product Portfolio
6.12.5 Grifols Recent Developments/Updates
6.13 Biogen
6.13.1 Biogen Corporation Information
6.13.2 Biogen Human Factor VIII Concentrate Description and Business Overview
6.13.3 Biogen Human Factor VIII Concentrate Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Biogen Human Factor VIII Concentrate Product Portfolio
6.13.5 Biogen Recent Developments/Updates
6.14 Octapharma
6.14.1 Octapharma Corporation Information
6.14.2 Octapharma Human Factor VIII Concentrate Description and Business Overview
6.14.3 Octapharma Human Factor VIII Concentrate Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Octapharma Human Factor VIII Concentrate Product Portfolio
6.14.5 Octapharma Recent Developments/Updates
6.15 NovoNordisk
6.15.1 NovoNordisk Corporation Information
6.15.2 NovoNordisk Human Factor VIII Concentrate Description and Business Overview
6.15.3 NovoNordisk Human Factor VIII Concentrate Sales, Revenue and Gross Margin (2019-2024)
6.15.4 NovoNordisk Human Factor VIII Concentrate Product Portfolio
6.15.5 NovoNordisk Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Human Factor VIII Concentrate Industry Chain Analysis
7.2 Human Factor VIII Concentrate Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Human Factor VIII Concentrate Production Mode & Process
7.4 Human Factor VIII Concentrate Sales and 麻豆原创ing
7.4.1 Human Factor VIII Concentrate Sales Channels
7.4.2 Human Factor VIII Concentrate Distributors
7.5 Human Factor VIII Concentrate Customers
8 Human Factor VIII Concentrate 麻豆原创 Dynamics
8.1 Human Factor VIII Concentrate Industry Trends
8.2 Human Factor VIII Concentrate 麻豆原创 Drivers
8.3 Human Factor VIII Concentrate 麻豆原创 Challenges
8.4 Human Factor VIII Concentrate 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Pfizer
Novo Nordisk A/S
Shire (Baxter)
Bayer
GC Pharma
Shanghai Raas Corp
Hualan Biological
Shandong Taibang Biological Products
Shanghai Xinxing Medicine
SinoCell Tech
CSL
Grifols
Biogen
Octapharma
NovoNordisk
听
听
*If Applicable.